| 张玉卓 贺兆发 高艳辉 贾静 杨庆辉 韦宏.尼可地尔对冠心病合并2 型糖尿病不完全血运重建术后的疗效观察[J].现代生物医学进展英文版,2014,14(12):2299-2302. |
| 尼可地尔对冠心病合并2 型糖尿病不完全血运重建术后的疗效观察 |
| The efficacy of Nicorandil in Patients with Multivessel Coronary ArteryDisease Complicated with Type 2 Diabetes Undergoing IncompleteRevascularization |
| |
| DOI： |
| 中文关键词: 尼可地尔 冠心病 2 型糖尿病 不完全血运重建 |
| 英文关键词: Nicorandil Coronary artery disease Type 2 Diabetes Incomplete revascularization |
| 基金项目: |
|
| Hits: 767 |
| Download times: 1154 |
| 中文摘要: |
| 目的：比较尼可地尔与单硝酸异山梨酯对冠心病合并2 型糖尿病患者不完全血运重建术后的疗效。方法：入选112 例经皮
冠状动脉介入治疗（PCI）部分血运重建的冠心病合并2 型糖尿病患者。随机分为2 组：尼可地尔组（5 mg，3 次/d，口服）60 例，单
硝酸异山梨酯组（50 mg，1 次/d，口服）52 例，两组患者均给予常规冠心病及糖尿病药物治疗。术后4 周末行运动负荷试验，观察
总运动时间，从开始运动到出现ST 段压低1.0 mv 和出现心绞痛的时间(s)，以及最大ST 段压低幅度，同时记录每周心绞痛发作
次数及硝酸甘油用量。结果：4 周后两组患者同服药前比较，从开始运动到出现ST 段压低1.0 mv 的时间延长，总运动时间延长，
从开始运动到出现心绞痛的时间延长，最大ST 段压低幅度降低（P<0.01），但尼可地尔组与单硝酸异山梨酯组比较无明显统计学
差异（P>0.05）；尼可地尔组每周心绞痛发作次数及硝酸甘油用量明显少于单硝酸异山梨酯组（P<0.05）。结论：尼可地尔可增加冠
心病合并糖尿病患者行不完全血运重建术后患者运动耐量，在减少心绞痛方面作用优于单硝酸异山梨酯。 |
| 英文摘要: |
| Objective:To assess the efficacy between Nicorandil and isosorbide mononitrate in patients with multivessel coronary
artery disease complicated with type 2 Diabetes undergoing incomplete revascularization by percutaneous coronary intervention(PCI).Methods:Patients (n=112) with multivessel coronary artery disease complicated with type 2 Diabetes suffered incomplete
revascularization by PCI were randomly divided into 2 groups: Nicorandil group (N=60) and isosorbide mononitrate group (N=52).
Exercise tolerance test, number of weekly angina attacks, nitroglycerin consumption were evaluated.Results:Both groups improve the
total exercise time and the time to 1 mv ST-segment depression in an exercise tolerance test,there was no significant difference between
the two groups,however, Nicorandil significantly decreased the number of angina attacks and nitroglycerin consumption.Conclusion:Nicorandil may have better antianginal effect than isosorbide mononitrate as treatment for patients after incomplete revascularization by
PCI with type 2 Diabetes. |
|
View Full Text
View/Add Comment Download reader |
| Close |
